HER2 in gastric cancer: A digital image analysis in pre-neoplastic, primary and metastatic lesions

Modern Pathology

Volumn 26, Issue 6, 2013, Pages 816-824

  Fusco, Nicola ^a   Rocco, Elena Guerini ^b   Del Conte, Claudia ^c   Pellegrini, Caterina ^b   Bulfamante, Gaetano ^b   Di Nuovo, Franca ^d   Romagnoli, Solange ^b   Bosari, Silvano ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Ospedale Civile di Legnano   (Italy)

^d AO 'Guido Salvini'   (Italy)

Author keywords

Digital image analysis; ERBB2; gastric cancer; HER2; tumor heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ALGORITHM; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; DIGITAL IMAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SCORING SYSTEM; STAINING; STOMACH CANCER; TISSUE MICROARRAY; TUMOR INVASION;

EID: 84878530643     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.228     Document Type: Article

References (79)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts and Figures 2007. American Cancer Society, 2007: Atlanta, GA.
2. Cervantes A, Rosello S, Roda D, et al. The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol 2008;19(Suppl 5):103-107.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
4. Nicholas G, Cripps C, Au H-P, et al. Phase II of trastuzumab and cisplatin in patients who progressed while on chemotherapy for metastatic or locally advanced HER2 positive gastric cancer. Ann Oncol 2006;17(Suppl 9):316.
5. Cortes-Funes H, Rivera F, Ales I, et al. Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. J Clin Oncol 2007;15:18S.
6. De Vita F, Giuliani F, Silvestris N, et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews 2010;36:S11-S15.
7. Alroy I, Yarden Y. The erbB signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand receptor interactions. FEBS Let 1997;410:83-86.
8. Risio M, De Rosa G, Sarotto I, et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003;23:1381-1387.
9. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
10. Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185 (HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005;91:513-521.
11. Kanta SY, Yamane T, Dobashi Y, et al. Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 2006;37:1333-1343.
12. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833-837.
13. Tapia C, Glatz K, Novotny H, et al. Close association between HER2 amplification and overexpression in human tumours of non-breast origin. Mod Pathol 2007;20:192-198.
14. Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. Proc Am Soc Clin Oncol 2004;23:325.
15. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
16. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
17. Marx AH, Tharun L, Muth J, et al. HER2 amplification is highly homogeneous in gastric cancer. Hum Pathol 2009;40:769-777.
18. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009;135: 1331-1339.
19. Allgayer H, Babic R, Uwe Gruetzner K, et al. C-ErbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumour-associated protease systems. J Clin Oncol 2000;18:2201-2209.
20. Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-493.
21. Yan B, Yau EX, Omar SSB, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-842.
22. Lee KE, Lee HJ, Kin YH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173-179.
23. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
24. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of clinical oncology/college of American pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
25. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;1-14.
26. Yamamoto T, Ikawa S, Akaiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234.
27. Ooi A, Kobayashi M, Mai M, et al. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 1998;78:345-351.
28. Dursun A, Poyraz A, Celik B, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki- 67. Pathol Oncol Res 1999;5:104-106.
29. Gurel S, Dolar E, Yerci O, et al. The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999;27:74-78.
30. Ougulkov A, Yamashita K, Bilim V, et al. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int J Colorectal Dis 2003;18:160-166.
31. Sanz Ortega J, Steinberg SM, Moro E, et al. Comparative study of tumour angiogenesis and immunohistochemistry for p53, c-ErbB2, myc and EGFr as prognostics factors in gastric cancer. Histol Histopathol 2000;15:455-462.
32. Aoyagi K, Kohfuji K, Yano S, et al. Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma. Kurume Med J 2001;48:197-200.
33. Koeppen HKW, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001;38: 96-104.
34. Pinto de Sousa J, David L, Almeida R, et al. c-erb B-2 expression is associated with tumour location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002;10: 247-256.
35. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
36. FDA/CDRH Premarket Notification Database. FDA. gov 2007; Available http://www.accessdata.fda.gov/ cdrh-docs/pdf7/K071128.pdf [accessed July 1, 2012].
37. Dobson L, Conway C, Hanley A, et al. Image analysis as an adjunct to manual HER2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology 2010;57:27-38.
38. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011;58:383-394.
39. Li Zhang X, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-2118.
40. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and realtime quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393.
41. Park DI, Yun JW, Park JH, et al. HER2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379.
42. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278.
43. Ishikawa T, Kobayashi M, Mai M, et al. Amplification of the c-erbB-2 (HER2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 1997;151:761-768.
44. Varis A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 2004;109:548-553.
45. Moelans CB, van Diest PJ, Milne AN, et al. HER2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2010;2011:674182.
46. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011;18:53-59.
47. Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011;59:822-831.
48. Kim JG, Ryoo BY, Park YH, et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008;61:301-307.
49. Barone C, Corsi DC, Pozzo C, et al. Treatment of patients with advanced gastric carcinoma with a 5- fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer 1998;82:1460-1467.
50. Richman SD, Chambers P, Seymour MT, et al. Intratumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34:61-66.
51. Oltedal S, Aasprong OG, Mller JH, et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis 2011;26:1271-1277.
52. Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011;18:2833-2840.
53. Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 2011;59:832-840.
54. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344-2348.
55. Xu R, Perle MA, Inghirami G, et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15: 116-124.
56. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-1769.
57. Park K, Han S, Kim HJ, et al. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006;48: 702-707.
58. Santiago MP, Vázquez-Boquete A, Fernández B, et al. Whether to determine HER2 status for breast cancer in the primary tumour or in the metastasis. Histol Histopathol 2009;24:675-682.
59. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;104:1372-1376.
60. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neuprotein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
61. Lodato RF, Maguire HC Jr, Greene MI, et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-454.
62. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990;21:1164-1167.
63. Allred DC, Clark GM, Molina R, et al. Overexpression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-979.
64. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/ neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002;15:1318-1325.
65. Fassan M, Mastracci L, Grillo F, et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012;61:769-776.
66. Villanacci V, Rossi E, Grisanti S, et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol Dietol 2008;54: 347-353.
67. Rossi E, Grisanti S, Villanacci V, et al. HER-2 overexpression/ amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med 2009;13:3826-3833.
68. Rossi E, Villanacci V, Bassotti G, et al. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 2010;57:81-89.
69. Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907.
70. Roses RE, Paulson EC, Sharma A, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1386-1389.
71. Yonemura Y, Sugiyama K, Fushida S, et al. Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer. Anal Cell Pathol 1991;3:343-350.
72. Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23:2656-2662.
73. Sasano H, Date F, Imatani A, et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993;24:584-589.
74. Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992;49: 209-212.
75. Yoon QSHH, Sukov WR, Wiktor AE, et al. HER2 expression/amplification: frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol 2011;29(Suppl):(Abstr 4012).
76. Webb A, Scott-Mackie P, Cunningham D, et al. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer 1996;32:63-68.
77. Terashima MAO, Kitada K, Ichikawa W, et al. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. J Clin Oncol 2011;29 (Suppl):(Abstr 4013).
78. Thompson S, Sullivan T, Davies R, et al. Her- 2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011;18:2010-2017.
79. Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24.